Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar
Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit declining as much as 13% this year.
Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit declining as much as 13% this year.
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
